Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
EF Hutton has initiated coverage on ImmunityBio Inc. (NASDAQ:IBRX), a vertically integrated biotechnology company developing ...
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
Parade on MSN8d
This Is One of the Most Common Signs of Bladder Cancer, According to a UrogynecologistDr. Kobashi says that the most common symptom of bladder cancer is blood in urine. The blood can range from bright red to a ...
Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...
With its lead candidate in a phase 3 trial for a rare eye cancer, Aura Biosciences is looking to expand the drug into a more ...
Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal ...
Matthew R. Zibelman, MD, discusses differing opinions in muscle-invasive bladder cancer treatment he heard when moderating a Case-Based Roundtable event.
Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...
To mark Breast Cancer Awareness Month, we speak to inspiring Singaporeans about their journey in battling and overcoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback